Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Rheumatology

The Biology of AAV: Why Your Body Attacks Itself

At a Glance

In ANCA-associated vasculitis (AAV), the immune system mistakenly creates autoantibodies (PR3 or MPO) that activate white blood cells called neutrophils. This sets off a chain reaction of intense inflammation that damages small blood vessels, often affecting the kidneys, lungs, and sinuses.

While an AAV diagnosis can feel like a series of complex acronyms, the biology behind it is a story of “friendly fire.” Your immune system, which is designed to protect you, begins to target your own healthy tissues. Specifically, it targets your neutrophils—a type of white blood cell that serves as your body’s “first responders” to infection [1][2].

The Biological Chain Reaction

In a healthy body, neutrophils travel through the bloodstream, waiting for a signal to attack germs. In AAV, this process goes wrong through a three-step biological chain reaction:

  1. The “Priming”: Something—perhaps a recent infection or environmental factor—puts your neutrophils on high alert, or “primes” them [2].
  2. The ANCA Attack: Your body produces autoantibodies called ANCA (Anti-Neutrophil Cytoplasmic Antibodies). These antibodies latch onto the “primed” neutrophils, accidentally switching them “ON” when there is no infection to fight [1].
  3. The Complement Explosion: Once activated, these neutrophils release signals that trigger the alternative complement pathway, specifically a protein called C5a [3]. C5a acts like a megaphone, screaming for more neutrophils to rush to the area. This “loop” creates intense inflammation that damages the walls of your small blood vessels [4][5].

Mapping the Subtypes

AAV is an “umbrella term” divided into three main clinical subtypes. While they share the same basic “friendly fire” mechanism, they often affect different organs and are associated with different ANCA types [6].

Subtype Full Name Key Distinguishing Features Common Antibody
GPA Granulomatosis with Polyangiitis Forms granulomas (clumps of inflammatory cells); often affects the nose, sinuses, and lungs [1][7]. PR3-ANCA [8]
MPA Microscopic Polyangiitis Typically lacks granulomas; very frequently involves the kidneys and can cause lung bleeding [1][9]. MPO-ANCA [8]
EGPA Eosinophilic Granulomatosis with Polyangiitis Closely linked to asthma and high levels of eosinophils (another type of white blood cell) [10][11]. MPO-ANCA (or ANCA-negative) [10]

PR3 vs. MPO: Why the Antibody Matters

Your doctor will test your blood for two specific types of ANCA. Knowing which one you have helps your care team predict how the disease might behave.

  • PR3-ANCA: Most common in patients with GPA. These patients may have a slightly higher risk of the disease returning (relapse) after treatment, requiring more vigilant long-term monitoring [8][12].
  • MPO-ANCA: Most common in patients with MPA and the vasculitic form of EGPA. This antibody is often associated with more severe kidney involvement [8][13].

The Role of “Pauci-Immune” Inflammation

If you have a biopsy, you might see the term pauci-immune. This is a Latin-based term meaning “few-immune.” It tells the doctor that the damage in your blood vessels isn’t caused by a buildup of “immune complexes” (clumps of antibodies), but rather by the direct attack of those over-activated neutrophils [6][10]. This distinction is vital because it confirms to your doctor that AAV-specific treatments—rather than general treatments for other types of kidney or lung disease—are necessary to stop the damage.

Back to Home

Common questions in this guide

What does it mean if my blood test is positive for PR3-ANCA or MPO-ANCA?
Testing positive for PR3 or MPO antibodies helps your doctor identify your specific AAV subtype. PR3 is most common in GPA and may carry a higher risk of relapse, while MPO is typical in MPA and EGPA, and is often linked to more severe kidney involvement.
What is the difference between GPA, MPA, and EGPA?
These are the three main subtypes of AAV. GPA often forms inflammatory clumps called granulomas in the respiratory tract, MPA frequently involves the kidneys without granulomas, and EGPA is closely linked to asthma and high levels of eosinophils in the blood.
What does 'pauci-immune' mean on my biopsy report?
Pauci-immune means there are very few clumps of antibodies in the damaged tissue. This confirms to your doctor that the blood vessel damage is caused by a direct attack from over-activated immune cells, requiring specific AAV treatments to stop the inflammation.
How does the alternative complement pathway (C5a) affect my disease?
In AAV, a protein in this pathway called C5a gets triggered and acts like an alarm, calling more inflammatory immune cells to the area. This creates an intense, continuous loop of inflammation that damages your small blood vessels and organs.
Can environmental factors or infections cause AAV?
Certain environmental exposures, such as breathing in silica dust, or recent severe infections can act as a trigger. These factors may 'prime' your white blood cells, putting your immune system on high alert before the autoimmune attack begins.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my labs, am I positive for PR3-ANCA or MPO-ANCA, and how does that influence my diagnosis?
  2. 2.Do my biopsy results show any signs of granulomas or 'pauci-immune' inflammation?
  3. 3.How is the alternative complement pathway (C5a) affecting my kidneys or lungs specifically?
  4. 4.Does my subtype (GPA, MPA, or EGPA) make me more likely to experience a relapse in the future?
  5. 5.Could a C5a receptor inhibitor like avacopan be beneficial for my specific biological profile?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    [ANCA-associated small-vessel vasculitides].

    Bayrashevskaya AV, Degtyareva ND, Radenska-Lopovok SG

    Arkhiv patologii 2022; (84(1)):50-58 doi:10.17116/patol20228401150.

    PMID: 35166479
  2. 2

    Overview of the Pathogenesis of ANCA-Associated Vasculitis.

    Xiao H, Hu P, Falk RJ, Jennette JC

    Kidney diseases (Basel, Switzerland) 2016; (1(4)):205-15 doi:10.1159/000442323.

    PMID: 27536680
  3. 3

    C5a receptor 1 promotes autoimmunity, neutrophil dysfunction and injury in experimental anti-myeloperoxidase glomerulonephritis.

    Dick J, Gan PY, Ford SL, et al.

    Kidney international 2018; (93(3)):615-625 doi:10.1016/j.kint.2017.09.018.

    PMID: 29241626
  4. 4

    The complement system in antineutrophil cytoplasmic antibody-associated vasculitis: pathogenic player and therapeutic target.

    Mazzariol M, Manenti L, Vaglio A

    Current opinion in rheumatology 2023; (35(1)):31-36 doi:10.1097/BOR.0000000000000914.

    PMID: 36301247
  5. 5

    Pathogenesis and pathology of anti-neutrophil cytoplasmic antibody（ANCA）-associated vasculitis.

    Tsukui D, Kimura Y, Kono H

    Journal of translational autoimmunity 2021; (4()):100094 doi:10.1016/j.jtauto.2021.100094.

    PMID: 33912820
  6. 6

    The clinical presentation and therapy of diseases related to anti-neutrophil cytoplasmic antibodies (ANCA).

    Weiner M, Segelmark M

    Autoimmunity reviews 2016; (15(10)):978-82.

    PMID: 27481040
  7. 7

    Pathogenesis of Pulmonary Manifestations in ANCA-Associated Vasculitis and Goodpasture Syndrome.

    Fouka E, Drakopanagiotakis F, Steiropoulos P

    International journal of molecular sciences 2024; (25(10)) doi:10.3390/ijms25105278.

    PMID: 38791316
  8. 8

    Performance of MPO-ANCA and PR3-ANCA immunoassays for the stratification of specific ANCA-associated vasculitis: A systematic review and meta-analysis.

    Walker BS, Peterson LK, Koening C, et al.

    Autoimmunity reviews 2022; (21(6)):103100 doi:10.1016/j.autrev.2022.103100.

    PMID: 35452854
  9. 9

    Clinical Characteristics and Outcomes of Patients With ANCA-Associated Vasculitides in a Colombian Hospital.

    Santacruz-Sandoval E, López-Bonilla J, Guevara-Calderón LA, et al.

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2022; (28(2)):e491-e497 doi:10.1097/RHU.0000000000001775.

    PMID: 35192595
  10. 10

    Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCA.

    Nishi R, Koike H, Ohyama K, et al.

    Neurology 2020; (94(16)):e1726-e1737 doi:10.1212/WNL.0000000000009309.

    PMID: 32217776
  11. 11

    Granulomatous Vasculitis.

    Sharma A, Dogra S, Sharma K

    Dermatologic clinics 2015; (33(3)):475-87.

    PMID: 26143427
  12. 12

    Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis.

    McClure ME, Wason J, Gopaluni S, et al.

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2019; (25(5)):217-223 doi:10.1097/RHU.0000000000001030.

    PMID: 30896460
  13. 13

    Proteinase 3-specific antineutrophil cytoplasmic antibody-associated vasculitis.

    Falde SD, Fussner LA, Tazelaar HD, et al.

    The Lancet. Rheumatology 2024; (6(5)):e314-e327 doi:10.1016/S2665-9913(24)00035-3.

    PMID: 38574742

This page explains the biology and subtypes of AAV for educational purposes only. Always consult your rheumatologist or specialist team for medical advice regarding your specific condition, symptoms, and lab results.

Get notified when new evidence is published on Anti-neutrophil cytoplasmic antibody-associated vasculitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.